Continental appetite

Having cut its teeth on the successful U.S. launch of Jakafi ruxolitinib, Incyte Corp. now has global aspirations for the rest of its pipeline. The acquisition of Ariad Pharmaceuticals Inc.'s European commercial business is intended to provide a self-funding infrastructure from which to launch new products, starting with immuno-oncology candidate epacadostat in 2019.

Incyte also is on the lookout for similar vehicles in the Asia-Pacific region...